Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Opinion and Comment
Nature Biotechnology 26, 739–740 (1 July 2008) | doi:10.1038/nbt0708-739
HLA-haplotype banking and iPS cells
&
Abstract
To the editor: The production of induced pluripotent stem (iPS) cell lines from human somatic cells, such as skin fibroblasts, recently reported in your January issue and elsewhere, opens the exciting new possibility of producing personalized pluripotent stem cell lines from individual patients without using human oocytes or embryos. In addition to circumventing ethical problems associated with human embryonic stem (ES) cells, this new approach could also address immunological rejection associated with cell therapies because iPS cell lines could be created with human leukocyte antigen (HLA)-haplotypes matching those of individual patients.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
